InGeNA, Pathology Technology Australia Respond to Government Announcement on Genetic Discrimination

InGeNA and Pathology Technology Australia welcomes the Federal Government’s announcement of a ban on genetic discrimination in life insurance. This is an important step toward removing barriers that have long prevented Australians from fully benefiting from genomic medicine and genetic testing. 

“Genomics and precision medicine are at the forefront of transforming healthcare, offering unprecedented opportunities to improve patient outcomes. The removal of genetic discrimination in life insurance is crucial to unlocking these benefits for all Australians. The industry stands united behind the ban to ensure that everyone can confidently access genetic testing without fear of repercussions.” Dr Erin Evans, CEO of InGeNA. 

This issue has brought together industry leaders and patient advocacy groups in a collective effort to address the significant barriers facing individuals considering genetic testing. The collaboration between these groups highlights the shared commitment to improving healthcare access and ensuring that Australians are empowered to make informed decisions about their health without fear of discrimination.  

We would also like to acknowledge the recommendations report by Dr. Jane Tiller and Professor Paul Lacaze and the tireless advocacy of Dr Tiller on this issue.  

We remain committed to promoting the benefits of genomic medicine and ensuring that this ban is supported by the necessary legislation, so these protections can become a reality.